Diabetes Care: Metformin lowers cholesterol levels in people with diabetes
Release time:
2018-05-24
In addition to affecting blood sugar levels, metformin also affects blood lipid levels. In a recent research paper published in the international magazine Diabetes Care, researchers from the German Diabetes Research Center found that metformin may also affect the body's blood lipid levels. In particular, levels of harmful LDL cholesterol can be reduced.
In addition to affecting blood sugar levels, metformin also affects blood lipid levels. In a recent research paper published in the international magazine Diabetes Care, researchers from the German Diabetes Research Center found that metformin may also affect the body's blood lipid levels. In particular, levels of harmful LDL cholesterol can be reduced.
In the article, researchers studied participants who participated in the large-scale German study KORA, analyzed 1,800 blood samples from the participants, and used a comprehensive method to investigate and analyze the metabolites of the participants' bodies and the participants. The genetic characteristics of the organism. The results show that taking metformin in patients with type 2 diabetes can effectively change the levels of metabolites in the patient's body, and the taking of metformin is directly related to the significant decrease in the level of low-density lipoprotein cholesterol in the patient's body. Low-density lipoprotein cholesterol is considered to cause arteriosclerosis. Atherosclerosis, in turn, is a risk factor for cardiovascular disease.
The researchers then conducted comprehensive consideration and analysis based on the patient's genetic information and the concentration of metabolites, and identified the metabolites and genes involved in their respective regulatory pathways; Professor Rui Wang-Sattler said, "We speculate that the intake of metformin will pass through The AMPK pathway affects the level of low-density lipoprotein cholesterol, resulting in the down-regulation of the expression of genes FADS1 and FADS2. The researchers' study of three FADS-dependent lipid metabolites also confirmed the above conclusion. Subsequently, the researchers will go Analyze and study the mechanism by which metformin induces a decrease in LDL cholesterol levels.
The researchers said that metformin may indeed have an additional beneficial effect on cardiovascular disease in patients with diabetes. So far, the mechanism of this action is not clear, but later researchers will use more in-depth studies to clarify how metformin reduces diabetes. The patient's low-density lipoprotein levels.
Address: Nanjing Life Science and Technology Innovation Park, 568 Longmian Avenue, Jiangning District, Nanjing City, Jiangsu Province
Copyright©2023 Nanjing Jiqun Pharmaceutical Technology Co., Ltd.
Website construction: www.300.cn Nanjing